Literature DB >> 7120546

Transverse colon conduit: a method of urinary diversion after pelvic irradiation.

S Beckley, Z Wajsman, J E Pontes, G Murphy.   

Abstract

Patients with pelvic malignancies often require irradiation as part of the treatment protocol or as definitive treatment for the malignancy. Subsequent urinary diversion with the low lying small bowel or the descending colon often results in increased morbidity. Therefore, a method of urinary diversion using the transverse colon conduit in an end-to-end ureterocolic anastomosis as described by Wallace was used. Several advantages with this method are identifiable easily and are described. The satisfactory results in the last 30 patients who underwent this procedure after pelvic irradiation are presented. The ureterocolic anastomosis with reflux is of particular importance since it allows retrograde conduitograms to be performed at later dates to evaluate the urothelium for possible recurrent disease.

Entities:  

Mesh:

Year:  1982        PMID: 7120546     DOI: 10.1016/s0022-5347(17)52999-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  [Urinary diversion and colon: transverse conduit and transverse pouch].

Authors:  S A Ahyai; K Sayedahmed; O Engel; F Chun; R Dahlem; M Fisch
Journal:  Urologe A       Date:  2012-07       Impact factor: 0.639

2.  Neobladder formation after pelvic irradiation.

Authors:  Richard E Hautmann; Robert de Petriconi; Bjoern G Volkmer
Journal:  World J Urol       Date:  2008-11-20       Impact factor: 4.226

3.  Management of inoperable pelvic carcinomas with complex fistulas: a new approach.

Authors:  S J Hampson; S B Morris; E M Gordon; R J Shearer
Journal:  Ann R Coll Surg Engl       Date:  1994-05       Impact factor: 1.891

4.  Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation.

Authors:  Sam S Chang; Gregory L Alberts; Joseph A Smith; Michael S Cookson
Journal:  World J Urol       Date:  2004-09-21       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.